Acer therapeutics compliant with all nasdaq listing criteria

Newton, mass., dec. 29, 2022 (globe newswire) -- acer therapeutics inc. (nasdaq: acer), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that the nasdaq stock market llc has formally notified acer that the company has regained compliance with the $35 million market value of listed securities requirement, and otherwise satisfies all other criteria necessary, for continued listing on the nasdaq capital market. accordingly, the listing matter is now closed and the previously-scheduled hearing before the nasdaq hearings panel has been cancelled.
ACER Ratings Summary
ACER Quant Ranking